Immuno-oncology: spurred by the approval of first-generation checkpoint inhibitors in 2014, this important market has continued to grow exponentially, as deals are made not only around checkpoint inhibitors themselves, but also for related molecules and technologies to be used in synergy with them. Examine the origins of this important and growing area in this essential In Vivo report.
Author: Swarna Mehrotra, Oded Ben-Joseph, Ellen Baron
Published: 24 October 2018
Number of pages:2
Follow the origins of the immuno-oncology market in this examination of the deals and activities surrounding this important area. Such activity has resulted in a frenzy among big pharma and biotech to partner with or acquire those companies developing IO assets, making IO therapeutics the main driver in the competitive dealmaking area of oncology. Examine the deals and events from the first IO checkpoint inhibitor approvals (Merck & Co. Inc.’s Keytruda and Bristol-Myers Squibb Co.’s Opdivo, both in 2014) leading up to the present, where IO therapeutics continue to lead the competitive oncology area with emergent technologies like CAR-T therapies, and more.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.